Kura Oncology, Inc. (KURA) is a leading biopharmaceutical company that’s intensely focused on the development of innovative, precision oncology therapies. The company was established in 2014 and has its headquarters situated in San Diego, California. KURA’s innovative and diligent approach towards precision medicine aims to arm the healthcare industry with effective therapies that specifically target the clinicians’ most intractable patients with solid tumors.
KURA's proprietary portfolio includes potentially first-in-class therapeutics arisen from its profound understanding of the biological pathways implicated in cancer. It includes Tipifarnib, an inhibitor that’s currently under clinical development with an initial focus on HRAS mutant head and neck squamous cell carcinoma and tumors characterized by high CXCL12 expression.
Targeting mechanisms that drive cancer cell growth and survival, Kura Oncology is committed to the discovery and development of precision medicines. The company collaboratively works with an internationally renowned team of collaborators and advisors who are leading authorities in oncology drug development. Their team’s combined track record of drug discovery, clinical development, regulatory affairs, and commercialization is the driving force behind Kura’s objective of delivering life-changing treatments for patients.
KURA has shown robust growth since its inception and has emerged as a front-runner in the field of precision oncology, having illustrated promising results from clinical trials. Despite the high cost and risk associated with drug development, Kura Oncology has been successful in attracting investors' attention. This is predominantly due to its potential-becoming breakthroughs in the field of oncology.
Kura Oncology has consistently retained its commitment to patients suffering from various types of cancer. By remaining patient-focused, leveraging cutting-edge science and maintaining persistent innovation, Kura Oncology, Inc. practices a patient-first approach with the ultimate goal of substantially improving the quality of lives of those battling this devastating disease. The company’s ongoing dedication to employing the finest scientific methods in the development of novel cancer drugs undeniably places it at the forefront of the rapidly evolving landscape of precision oncology.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Kura Oncology, Inc. announced it will report its third-quarter 2026 financial results on Tuesday, November 10, 2026, after market close. Following the report, Kura’s management will host a webcast and conference call to discuss the results and provide a corporate update. The company, focused on precision medicines for cancer, has developed and commercialized KOMZIFTI® (ziftomenib) and is advancing other small molecule drug candidates.
This article analyzes Kura Oncology Inc. (NASDAQ: KURA), noting weak near and mid-term sentiment despite a positive long-term outlook. AI models have generated three trading strategies for different risk profiles, highlighting an exceptional 57.7:1 risk-reward setup. Key support and resistance levels are provided across various time horizons.
Kura Oncology, Inc. (KURA) has released a slideshow discussing data and its development strategy for menin inhibitors, specifically KO-7246, in the context of diabetes. The company's presentation was published in conjunction with an event, and the content is attributed to Seeking Alpha's transcripts team.
Kura Oncology Inc. (KURA) shares rallied 8% in after-hours trading following CEO Troy Edward Wilson's purchase of 100,000 shares worth $1.1 million. This insider buy signals strong confidence, especially after the company reported Q2 sales of $9.1 million for its main product, KOMZIFTI, a 57% increase from the previous quarter. KOMZIFTI is also progressing in clinical trials for earlier stages of blood cancer, and Kura is developing a second experimental drug, darlifarnib.